z-logo
Premium
Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery
Author(s) -
Xu Ke,
Chan Noel C.,
Hirsh Jack,
Ginsberg Jeffrey S.,
Bhagirath Vinai,
Kruger Paul,
Dale Brian,
Crowther Mark,
Whitlock Richard P.,
Li Chunjian,
Eikelboom John W.
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13109
Subject(s) - platelet , mean platelet volume , medicine , aspirin , thrombopoiesis , cardiology , antithrombotic , artery , surgery , haematopoiesis , stem cell , biology , megakaryocyte , genetics
Objectives An increased rate of platelet production is a possible cause of reduced antithrombotic response to once‐daily aspirin. Markers of immature platelets ( IP s), such as immature platelet count ( IPC ), immature platelet fraction ( IPF ), and mean platelet volume ( MPV ) might be useful for identifying patients who have an increase in their rate of platelet production. However, their potential as markers of platelet production has not been rigorously evaluated. We aimed to investigate the utility of the IPC , IPF , and MPV as surrogates for increased platelet production using coronary artery bypass grafting ( CABG ) as a model of enhanced thrombopoiesis. Methods Daily changes in platelet count, IPC , IPF , and MPV were followed in 45 patients undergoing CABG . Results The rise in IP markers preceded that in the platelet count. IPC (16% per day increase from nadir) but not IPF or MPV showed a significant and sustained rise, which paralleled the pattern observed with platelet count (18% per day increase from nadir). Conclusions Of the 3 markers, IPC was the most promising as surrogates for platelet production. Future studies should evaluate the utility of the IPC to identify patients with cardiovascular disease with reduced response to aspirin who might benefit from twice‐daily aspirin.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here